SCHEMBL6858138

SCHEMBL6858138

CC(Br)c1c(C=O)ccc2ccccc12

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP1A2 P05177 3/20 0.45
CYP2C9 P11712 2/20 0.45
CYP2C19 P33261 2/20 0.45
MAPT P10636 1/20 0.45
PTPN1 P18031 3/20 0.43
POLB P06746 2/20 0.43
ERN1 O75460 2/20 0.41
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
ALDH1A1 P00352 4/20 0.38
TDP1 Q9NUW8 3/20 0.38
TSHR P16473 3/20 0.38
CYP2A6 P11509 3/20 0.38
HSD17B10 Q99714 1/20 0.38
NCEH1 Q6PIU2 1/20 0.38
LMNA P02545 1/20 0.37
THRB P10828 1/20 0.37
BLM P54132 1/20 0.37
IMPDH2 P12268 1/20 0.36
GAA P10253 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2049662 0.73 TSHR (0.54) CYP1A2CYP2C9CYP2C19MAPTPTPN1
SCHEMBL950436 0.73 POLB (0.50) CYP1A2CYP2C9CYP2C19MAPTPTPN1
SCHEMBL19682355 0.73 CYP1A2 (0.54) CYP1A2CYP2C9CYP2C19MAPTMEN1
SCHEMBL29951280 0.73 TSHR (0.54) CYP1A2CYP2C9CYP2C19MAPTPTPN1
SCHEMBL30343616 0.73 POLB (0.50) CYP1A2CYP2C9CYP2C19MAPTPTPN1
SCHEMBL29521593 0.72 DNMT1 (0.48) CYP1A2CYP2C9CYP2C19MAPTPTPN1
SCHEMBL7643518 0.72 DNMT1 (0.48) CYP1A2CYP2C9CYP2C19MAPTPTPN1
SCHEMBL11763980 0.72 MAPT (0.58) CYP1A2CYP2C9CYP2C19MAPTPTPN1
SCHEMBL19682791 0.72 HPRT1 (0.42) CYP1A2CYP2C9CYP2C19MAPTPOLB
SCHEMBL197337 0.71 ERN1 (0.62) CYP1A2CYP2C9CYP2C19MAPTPTPN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-100395234-C Novel CB1 receptor inverse agonists HOFFMANN LA ROCHE (CH) 2008-06-18 CN disclosed
CN-101012193-A Novel CB 1 receptour inverse agonists HOFFMANN LA ROCHE (CH) 2007-08-08 CN disclosed
CN-1735593-A Novel CB1 receptor inverse agonists HOFFMANN LA ROCHE (CH) 2006-02-15 CN disclosed
US-6831075-B2 Administering to a host for inhibiting kinase activity a 5-heterocylcic subustituted pyrazolone derivative CEPHALON, INC. 2004-12-14 US disclosed
US-20030162775-A1 Heterocyclic substituted pyrazolones CEPHALON, INC. 2003-08-28 US disclosed
US-6455525-B1 Heterocyclic substituted pyrazolones CEPHALON, INC. 2002-09-24 US disclosed
EP-1226141-A1 HETEROCYCLIC SUBSTITUTED PYRAZOLONES CEPHALON, INC. (US) 2002-07-31 EP disclosed
WO-2001032653-A1 HETEROCYCLIC SUBSTITUTED PYRAZOLONES CEPHALON, INC. (US) 2001-05-10 WO disclosed
CN-1214047-A Novel aromatic piperazines derived from substituted cyclic azaalkanes, method for the production thereof, pharmaceutical compositions and use thereof as medicaments PF MEDICAMENT (FR) 1999-04-14 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030162775-A1 Heterocyclic substituted pyrazolones CYP3A4, CYP3A5, PDXK CYP1A2 106/4885CYP2C9 23/4885CYP2C19 6/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.